This study was designed to characterize the pharmacological profile of DS37001789, which is a structurally novel piperazine derivative that acts as urotensin II (U-II) receptor antagonist. DS37001789 inhibited [125I]-U-II binding to human GPR14, U-II receptor, with an IC50 value 0.9 nM. Its potency was superior to that of ACT-058362, a nonpeptide U-II receptor antagonist whose IC50 was 120 nM. Human U-II–induced vascular contraction was blocked by DS37001789. The dose–response curve of DS37001789 in rats and monkeys did not show species differences, and it shifted to the right without any effects on the maximum vascular response. Moreover, orally administered DS37001789 dose-dependently prevented human U-II–induced blood pressure elevation in mice, and this effect was significant at dose and higher dose (30 and 100 mg/kg), and its potency was superior to that of ACT-058362 (100 mg/kg). These results suggest that DS37001789 is a highly potent U-II receptor antagonist both in vitro and in vivo, with no marked species difference. DS37001789 would be a useful tool to clarify the physiological roles of U-II/GPR14 system. In addition, it can serve as a novel therapeutic agent for diseases in which the U-II/GPR14 system is upregulated, such as hypertension, heart failure, renal dysfunction, and diabetes.
*End-Organ Disease Laboratories, Daiichi-Sankyo Co, Ltd, Shinagawa-ku, Tokyo, Japan;
†Oncology Laboratories, Daiichi-Sankyo Co, Ltd, Shinagawa-ku, Tokyo, Japan;
‡Daiichi Sankyo Pharma Development, Daiichi-Sankyo, Inc, Basking Ridge, NJ; and
§Rare Disease & LCM Laboratories, Daiichi-Sankyo Co, Ltd, Shinagawa-ku, Tokyo, Japan.
Reprints: Mina Nishi, End-Organ Disease Laboratories, Daiichi-Sankyo Co, Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan (e-mail: firstname.lastname@example.org).
This study was funded by Daiichi Sankyo Co, Ltd.
The authors report no conflicts of interest.
Received March 29, 2018
Accepted August 07, 2018